Improved Survival From Graft-versus-host Disease Following Pediatric Small Intestinal Transplantation Through Reduction in Systemic Immunosuppression Altering T-cell Chimerism Dynamics.
Sandeep Potluri, Sarah Lawson, Shyla Kishore, Malobi Ogboli, Jane Hartley, Arun Alfred, Yvonne Wilson, Darius F Mirza, Khalid Sharif, Girish Gupte
{"title":"Improved Survival From Graft-versus-host Disease Following Pediatric Small Intestinal Transplantation Through Reduction in Systemic Immunosuppression Altering T-cell Chimerism Dynamics.","authors":"Sandeep Potluri, Sarah Lawson, Shyla Kishore, Malobi Ogboli, Jane Hartley, Arun Alfred, Yvonne Wilson, Darius F Mirza, Khalid Sharif, Girish Gupte","doi":"10.1097/TXD.0000000000001830","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Graft-versus-host-disease (GvHD) is an infrequent but serious complication of small intestinal transplantation in children, which is associated with a very poor prognosis. This study evaluated a novel strategy of managing GvHD in these patients through a reduction in immunosuppression.</p><p><strong>Methods: </strong>We conducted a retrospective review 108 consecutive pediatric patients at our center between 2005 and 2021, who had small intestinal transplantation. We assessed clinical features and outcomes as well as laboratory chimerism studies in cohorts of patients before and following a change in treatment strategy for GvHD from intensification to reduction in immunosuppression.</p><p><strong>Results: </strong>Fourteen percent of pediatric patients developed GvHD after small intestinal transplantation. A change in treatment strategy to a reduction in immunosuppression led to significantly improved overall survival (log rank <i>P</i> = 0.015). This improved survival correlated biologically with altered T-cell chimerism dynamics in blood; in patients who had a reduction in immunosuppression, there was abrogation of the rise in donor T-cell chimerism over time seen in the blood of patients who instead had intensification of their immunosuppression. This may be because of permitting recipient lymphocytes to have a host-versus-graft effect and outcompete donor-derived lymphocytes.</p><p><strong>Conclusions: </strong>Our results demonstrate that that altering the immunosuppressive therapy strategy, following clinical manifestations of GvHD such as a typical skin rash, from intensification to a reduction in immunosuppression led to significantly improved survival.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"11 7","pages":"e1830"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Direct","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TXD.0000000000001830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Graft-versus-host-disease (GvHD) is an infrequent but serious complication of small intestinal transplantation in children, which is associated with a very poor prognosis. This study evaluated a novel strategy of managing GvHD in these patients through a reduction in immunosuppression.
Methods: We conducted a retrospective review 108 consecutive pediatric patients at our center between 2005 and 2021, who had small intestinal transplantation. We assessed clinical features and outcomes as well as laboratory chimerism studies in cohorts of patients before and following a change in treatment strategy for GvHD from intensification to reduction in immunosuppression.
Results: Fourteen percent of pediatric patients developed GvHD after small intestinal transplantation. A change in treatment strategy to a reduction in immunosuppression led to significantly improved overall survival (log rank P = 0.015). This improved survival correlated biologically with altered T-cell chimerism dynamics in blood; in patients who had a reduction in immunosuppression, there was abrogation of the rise in donor T-cell chimerism over time seen in the blood of patients who instead had intensification of their immunosuppression. This may be because of permitting recipient lymphocytes to have a host-versus-graft effect and outcompete donor-derived lymphocytes.
Conclusions: Our results demonstrate that that altering the immunosuppressive therapy strategy, following clinical manifestations of GvHD such as a typical skin rash, from intensification to a reduction in immunosuppression led to significantly improved survival.
背景:移植物抗宿主病(GvHD)是儿童小肠移植的一种罕见但严重的并发症,其预后非常差。本研究评估了一种通过减少免疫抑制来治疗GvHD患者的新策略。方法:我们对2005年至2021年在我中心连续108例接受小肠移植的儿科患者进行回顾性分析。我们评估了GvHD治疗策略从强化到减少免疫抑制之前和之后患者队列的临床特征和结果以及实验室嵌合研究。结果:14%的儿童患者在小肠移植后发生GvHD。改变治疗策略减少免疫抑制导致总生存率显著提高(log rank P = 0.015)。这种生存率的提高与血液中t细胞嵌合动力学的改变具有生物学相关性;在免疫抑制减弱的患者中,随着时间的推移,在免疫抑制增强的患者血液中,供体t细胞嵌合现象的增加被消除了。这可能是因为允许受体淋巴细胞具有宿主对抗移植物的作用,并胜过供体来源的淋巴细胞。结论:我们的研究结果表明,改变免疫抑制治疗策略,在GvHD的临床表现(如典型的皮疹)之后,从免疫抑制增强到减少,可以显着提高生存率。